CLL treatment has greatly improved with the development of more specific agents, such as monoclonal antibodies (obinutuzumab, anti-CD20), kinase inhibitors (CAL-101/idelalisib, for PI3Kδ; ibrutinib, for Bruton tyrosine kinase; sotrastaurin, for PKCβ), or Bcl-2 inhibitors (ABT-263, ABT-199) [3, 5]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.